STAT3 Inhibitor
Inflammatory Diseases & Oncology
Lead OptimizationDevelopment candidate selection and IND-enabling targeted for 2026
Key Facts
Indication
Inflammatory Diseases & Oncology
Phase
Lead Optimization
Status
Development candidate selection and IND-enabling targeted for 2026
Company
About Altay Therapeutics
Altay Therapeutics is a private, preclinical-stage biotech focused on unlocking transcription factors as therapeutic targets. The company's core technology is a therapeutic area-agnostic platform that identifies novel allosteric sites on transcription factors to design highly selective oral inhibitors. With its lead FSHD program expected to enter IND-enabling studies in 2025 and a STAT3 inhibitor in lead optimization, Altay is positioning itself as a leader in a challenging but high-potential drug discovery space, supported by grants and recognition from major pharmaceutical companies.
View full company profile